Compare LI & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | TEVA |
|---|---|---|
| Founded | 2015 | 1901 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 30.2B |
| IPO Year | 2020 | N/A |
| Metric | LI | TEVA |
|---|---|---|
| Price | $17.29 | $30.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $20.91 | ★ $32.11 |
| AVG Volume (30 Days) | 4.3M | ★ 8.8M |
| Earning Date | 11-26-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | 0.62 |
| Revenue | ★ $17,952,966,790.00 | $16,776,000,000.00 |
| Revenue This Year | N/A | $4.62 |
| Revenue Next Year | $26.33 | $0.34 |
| P/E Ratio | ★ $27.26 | $50.57 |
| Revenue Growth | N/A | ★ 0.02 |
| 52 Week Low | $16.11 | $12.47 |
| 52 Week High | $33.12 | $31.99 |
| Indicator | LI | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 68.81 |
| Support Level | $16.34 | $31.17 |
| Resistance Level | $17.54 | $31.99 |
| Average True Range (ATR) | 0.38 | 0.55 |
| MACD | 0.19 | -0.20 |
| Stochastic Oscillator | 82.81 | 53.02 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.